Document is current
Any future updates will be listed below
-
Authors
Tozzi, Valeria D.
Banks, Helen
Ferrara, Lucia
Barbato, Angelo
Corrao, Giovanni
D’avanzo, Barbara
Di Fiandra, Teresa
Gaddini, Andrea
Compagnoni, Matteo Monzio
Sanza, Michele
Saponaro, Alessio
Scondotto, Salvatore
Lora, Antonio
- License Information
-
More Information
Article History
Received: 8 February 2023
Accepted: 6 June 2023
First Online: 7 September 2023
Declarations
:
: The Ethical Committee of the University of Milano-Bicocca evaluated and approved the study protocol (Protocol number 497, Year 2019) and established that the study (i) was exempt from patient informed consent (according to General Authorization for the Processing of Personal Data for Scientific Research Purposes Issued by the Italian Privacy Authority on August 10, 2018; ExternalRef removed); (ii) provides sufficient guarantees of individual record anonymity; and (iii) was designed according to quality standards of good practice of observational research based on secondary data. All methods were carried out in accordance with relevant guidelines and regulations or Declaration of Helsinki.
: Not applicable.
: GC received research support from the European Community (EC), the Italian Agency of Drug (AIFA), and the Italian Ministry for University and Research (MIUR). He took part to a variety of projects that were funded by pharmaceutical companies (i.e., Novartis, GSK, Roche, AMGEN and BMS). He also received honoraria as member of Advisory Board from Roche. No other potential conflicts of interest relevant to this article were disclosed.
